Karo Bio AB is acquiring the American biotechnology company Novalon Pharmaceutical Corporation based in Durham, North Carolina through a non- cash issue. “The acquisition of Novalon will strengthen Karo Bio’s technology base for the development of new drug substances that act upon nuclear receptors, which will make it possible to start several new projects and Read more about Karo Bio To Acquire Novalon[…]
Millennium Pharmaceuticals, Inc. has signed an agreement for an expanded alliance with MorphoSys AG. Under their agreement, MorphoSys AG will apply its proprietary HuCAL technology to generate human antibodies for a new target molecule in inflammatory disorders provided by Millennium. One of the objectives of the alliance is to develop fully human antibodies against targets Read more about Millennium And Morphosys Extend Collaboration[…]
Cell Genesys, Inc. has been issued a new United States Patent (No. 6,037,177) covering methods of production of its proprietary adeno- associated viral (AAV) gene delivery technology.The patent claims encompass technology for the large-scale production of AAV vectors for both clinical trials and potential product commercialisation. Cell Genesys‘ AAV patent portfolio now includes more than Read more about Cell Genesys Issued Additional Patent For AAV Gene Therapy Technology[…]
Chromagen, Inc. has announced an expansion of its existing agreement with Merck and Co. to develop and supply a broad range of novel pharmacogenomic assays. Chromagen will utilize its High Performance Signal Amplification (HPSA) platform technologies and StarBright fluorophores to develop assays for evaluating cell signaling pathways and genes that are emerging biological targets in Read more about Merck And Chromagen Expand Collaboration[…]
Gone are the days when a great physique was a characteristic feature of people serving in the armed forces or sports persons or athletes. The modern world in a health conscious world where a physically fit body is considered to be one of the most valuable assets that a human being can possess or is Read more about Synthobolic Extreme Synthol – Guaranteed Size and Muscle Definition[…]
Enzo Biochem, Inc. has received a patent from the U.S. Patent and Trademark Office that covers nucleic acid compositions and methods for editing and correcting certain abnormalities in genes. “Given the vast body of knowledge available through charting the human genome, the ability to correct inherent errors in the genes of a subject, and certain Read more about Enzo Biochem Gains Patent For Method To Alter Gene Abnormalities[…]
Xenometrix, Inc. has granted a worldwide license for gene expression profiling to Genometrix Incorporated, giving Genometrix access to claims covered in issued U.S. and European patents. The license is non-exclusive and covers the collection of gene expression profiles utilizing all platforms including microarrays. “Genometrix is a pioneer in chip-based platforms and is positioned well to Read more about Xenometrix Agrees Gene Expression Profiling Patent License To Genometrix[…]
DoubleTwist, Inc. has announced that Berlex Laboratories, Inc. has licensed DoubleTwist’s proprietary Clustering and Alignment Tools. As DoubleTwist’s best-selling product, the computational tools enable companies to quickly cluster and align high volumes of expressed sequence tags (ESTs) and genomic sequences into full-length gene sequences suitable for gene indexing and other applications in drug discovery. “We Read more about Berlex Licenses DoubleTwist Clustering And Alignment Tools[…]
Biacore International AB has entered into a collaborative agreement with SmithKline Beecham Pharmaceuticals, whereby the pharmaceutical giant will evaluate Biacore’s new prototype high performance system in preclinical and ADME drug screening studies.The collaboration marks yet another milestone in Biacore’s commitment to providing novel analytical systems to help the pharmaceutical industry increase the flow of high-quality Read more about Biacore Enters Collaboration With SmithKline Beecham[…]
ValiGene and Kimeragen announced today that they will merge to create ValiGen, a EuroAmerican functional genomics company. The newly formed ValiGen will combine the genomics platform under development at Valigene with chimeraplasty, the unique gene correction technology being developed at Kimeragen. The new company will pursue commercial opportunities for its technologies in three areas: ValiGen Read more about ValiGene And Kimeragen In Merger To Create Valigen[…]